Search

Displaying results 961 - 970 of 7062 in total
  1. Drug

    Tetanus immune globulin, human

    go.drugbank.com/drugs/DB11604
    ApprovedInvestigational

    Tetanus Immune Globulin is manufactured from human plasma [FDA Label]. It contains antibodies against tetanus toxoid and is primarily used as prophylaxis against tetanus in wounded patients.

    Products: Hypertet S/d, HyperTET S/D Injection 250 units
  2. Drug

    Misoprostol

    go.drugbank.com/drugs/DB00929
    ApprovedInvestigational

    [A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.

    Mixtures: DICLOENAC SODIUM and MISOPROSTOL DR, Diclofenac sodium and Misoprostol DR
  3. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  4. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    arthritis (RA) in combination with methotrexate. … [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient.

  5. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    bacterial DNA synthesis. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking

  6. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.

  7. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

  8. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). … [A261276] It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa.

  9. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE. … Dasiglucagon is a glucagon analog that acts to increase blood sugar levels.

  10. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371] … These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis.